These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 15714077

  • 1. Individualization of long-term enzyme replacement therapy for Gaucher disease.
    Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, International Collaborative Gaucher Group U.S. Regional Coordinators.
    Genet Med; 2005 Feb; 7(2):105-10. PubMed ID: 15714077
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic goals in the treatment of Gaucher disease.
    Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymańska A.
    Semin Hematol; 2004 Oct; 41(4 Suppl 5):4-14. PubMed ID: 15468045
    [Abstract] [Full Text] [Related]

  • 3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 4. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 5. Imiglucerase treatment in Gaucher's disease.
    Shah U, Nadeem N, Husen Y, Fadoo Z.
    J Ayub Med Coll Abbottabad; 2007 Aug; 19(2):56-9. PubMed ID: 18183722
    [Abstract] [Full Text] [Related]

  • 6. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Aug; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 7. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ.
    Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
    [Abstract] [Full Text] [Related]

  • 8. Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.
    Goldwater RS.
    J Intraven Nurs; 1996 Aug; 19(2):83-8. PubMed ID: 8852168
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic goals in Gaucher disease.
    Mistry P, Germain DP.
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [Abstract] [Full Text] [Related]

  • 11. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 12. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
    Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):107-10. PubMed ID: 20684886
    [Abstract] [Full Text] [Related]

  • 13. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
    Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM.
    Blood Cells Mol Dis; 2010 Jan 15; 44(1):41-7. PubMed ID: 19804996
    [Abstract] [Full Text] [Related]

  • 14. Gaucher disease: an overview of clinical characteristics and therapy.
    Kingma W.
    J Intraven Nurs; 1996 Jan 15; 19(2):79-82. PubMed ID: 8852167
    [Abstract] [Full Text] [Related]

  • 15. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 15; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
    Hollak CE, Belmatoug N, Cole JA, Vom Dahl S, Deegan PB, Goldblatt J, Rosenbloom B, van Dussen L, Tylki-Szymańska A, Weinreb NJ, Zimran A, Cappellini MD.
    Br J Haematol; 2012 Aug 15; 158(4):528-38. PubMed ID: 22640238
    [Abstract] [Full Text] [Related]

  • 17. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec 15; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 18. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K, Richards S, Yee J, Smith SE, Kingma W.
    Mol Genet Metab; 2007 Feb 15; 90(2):157-63. PubMed ID: 17079176
    [Abstract] [Full Text] [Related]

  • 19. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
    Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C.
    J Inherit Metab Dis; 2013 May 15; 36(3):543-53. PubMed ID: 22976765
    [Abstract] [Full Text] [Related]

  • 20. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.
    J Immunol Methods; 2011 Oct 28; 373(1-2):45-53. PubMed ID: 21846471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.